Literature DB >> 16284468

Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns.

Susan H Eshleman1, Donald R Hoover, Shu Chen, Sarah E Hudelson, Laura A Guay, Anthony Mwatha, Susan A Fiscus, Francis Mmiro, Philippa Musoke, J Brooks Jackson, Newton Kumwenda, Taha Taha.   

Abstract

The administration of single-dose nevirapine to women in labor and their infants can prevent HIV-1 mother-to-child transmission. We examined nevirapine resistance in infants who were HIV-1 infected despite single-dose nevirapine prophylaxis, including 18 Ugandan infants (HIVNET 012 trial, nine subtype A and nine subtype D) and 23 Malawian infants (NVAZ trial, all subtype C). Nevirapine resistance was more frequent in infants with subtype C than with subtypes A and D (87 versus 50%, P = 0.016).

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16284468     DOI： 10.1097/01.aids.0000194800.43799.94

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  29 in total

1.  HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine.

Authors:  Gillian M Hunt; Ashraf Coovadia; Elaine J Abrams; Gayle Sherman; Tammy Meyers; Lynn Morris; Louise Kuhn
Journal:  AIDS       Date:  2011-07-31       Impact factor: 4.177

Review 2.  Minority variants of drug-resistant HIV.

Authors:  Sara Gianella; Douglas D Richman
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

3.  Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance.

Authors:  Christopher F Rowley; Christian L Boutwell; Esther J Lee; Iain J MacLeod; Heather J Ribaudo; M Essex; Shahin Lockman
Journal:  AIDS Res Hum Retroviruses       Date:  2010-03       Impact factor: 2.205

4.  Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi.

Authors:  Sherry L Farr; Julie A E Nelson; Thokozani J Ng'ombe; Athena P Kourtis; Charles Chasela; Jeffrey A Johnson; Angela D M Kashuba; Gerald L Tegha; Jeffrey Wiener; Joseph J Eron; Harriet N Banda; Mwanangwa Mpaso; Jonathan Lipscomb; Chrissie Matiki; Susan A Fiscus; Denise J Jamieson; Charles van der Horst
Journal:  J Acquir Immune Defic Syndr       Date:  2010-08       Impact factor: 3.731

5.  Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis.

Authors:  Jessica Fogel; Donald R Hoover; Jin Sun; Lynne M Mofenson; Mary G Fowler; Allan W Taylor; Newton Kumwenda; Taha E Taha; Susan H Eshleman
Journal:  AIDS       Date:  2011-04-24       Impact factor: 4.177

6.  Minor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapine-containing ART.

Authors:  Iain J MacLeod; Christopher F Rowley; Ibou Thior; Carolyn Wester; Joseph Makhema; Max Essex; Shahin Lockman
Journal:  J Clin Virol       Date:  2010-04-27       Impact factor: 3.168

7.  Predictors of early and late mother-to-child transmission of HIV in a breastfeeding population: HIV Network for Prevention Trials 012 experience, Kampala, Uganda.

Authors:  Francis A Mmiro; Jim Aizire; Anthony K Mwatha; Susan H Eshleman; Deborah Donnell; Mary Glenn Fowler; Clemensia Nakabiito; Philippa M Musoke; J Brooks Jackson; Laura A Guay
Journal:  J Acquir Immune Defic Syndr       Date:  2009-09-01       Impact factor: 3.731

8.  Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission.

Authors:  Jessica D Church; Saad B Omer; Laura A Guay; Wei Huang; Jessica Lidstrom; Philippa Musoke; Francis Mmiro; J Brooks Jackson; Susan H Eshleman
Journal:  J Infect Dis       Date:  2008-10-01       Impact factor: 5.226

9.  Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy.

Authors:  Allison Agwu; Jane C Lindsey; Kimberly Ferguson; Haili Zhang; Stephen Spector; Bret J Rudy; Stuart C Ray; Steven D Douglas; Patricia M Flynn; Deborah Persaud
Journal:  AIDS Patient Care STDS       Date:  2008-07       Impact factor: 5.078

10.  Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants.

Authors:  Anitha Moorthy; Amita Gupta; Ramesh Bhosale; Srikanth Tripathy; Jayagowri Sastry; Smita Kulkarni; Madhuri Thakar; Renu Bharadwaj; Anju Kagal; Arvind V Bhore; Sandesh Patil; Vandana Kulkarni; Varadharajan Venkataramani; Usha Balasubramaniam; Nishi Suryavanshi; Carrie Ziemniak; Nikhil Gupte; Robert Bollinger; Deborah Persaud
Journal:  PLoS One       Date:  2009-01-01       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.